ReviewBioorganic & medicinal chemistry2026
Emerging chemical strategies for CD38 inhibition: restoring NAD
Zeyu Zhang, Arshad J Ansari, Ethan R Fayne, Yong Zhang
Abstract readReview
In one paragraphReview in Bioorganic & medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Zeyu ZhangDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States.
Arshad J AnsariDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States.
Ethan R FayneDornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, United States.
Yong ZhangDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States; Department of Chemistry, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, United States; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, United States; Research Center for Liver Diseases, University of Southern California, Los Angeles, CA 90089, United States. Electronic address: yongz@usc.edu.
Funding
Chemistry and Biology of ADP-Ribosylation-Dependent SignalingR35GM137901 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Yong Zhang · 2020 to 2026
$2.5MReprogramming Exosomes for Biomedical ApplicationsR01EB031830 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, YONG · 2021 to 2024
$2.1MReprogramming Exosomes for Novel Immunotherapy of Triple Negative Breast CancerR01CA276240 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Yong Zhang · 2023 to 2026
$2.0MNCI NIH HHS R01 CA276240NIBIB NIH HHS R01 EB031830NIGMS NIH HHS R35 GM137901
6 · The paper itselfAbstract
Cluster of differentiation 38 (CD38) is a multifunctional ectoenzyme regulating immune functions, calcium signaling, and nicotinamide adenine dinucleotide (NAD
Indexed as
ADP-ribosyl Cyclase 1Enzyme InhibitorsMembrane GlycoproteinsNADSmall Molecule LibrariesAnimalsHumansMolecular StructureADP-ribosyl Cyclase 1CD38 protein, humanEnzyme InhibitorsMembrane GlycoproteinsNADSmall Molecule LibrariesAgingCancerCD38InflammationInhibitorMetabolismNAD+Signaling
Identifiers
PMID42033923
PMCPMC13138852
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390